ANI Pharmaceuticals Inc (OQ:ANIP)

Business Focus: Biotechnology & Medical Research

Sep 11, 2019 08:30 am ET
ANI Pharmaceuticals Announces Launch of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL
BAUDETTE, Minn., Sept. 11, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Vancomycin HCl for Oral Solution, 250mg per 5mL (the generic equivalent to ANI's Vancocin® for Oral Solution).  To facilitate ease of administration the drug now includes a mixed berry taste, can be administered via nasogastric tube and does not contain any ingredients made with gluten-containing grain (wheat, barley, rye).  The dye-free product is delivered in a single bottle format requiring simple reconstitution and offers dosing flexibility achieved through the a...
Aug 07, 2019 08:30 am ET
ANI Pharmaceuticals Reports Second Quarter Results
BAUDETTE, Minn., Aug. 7, 2019 /PRNewswire/ --...
Jul 31, 2019 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2019 Financial Results
BAUDETTE, Minn., July 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2019 financial results on Wednesday, August 7, 2019, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com. ...
May 09, 2019 08:30 am ET
May 02, 2019 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2019 Financial Results
BAUDETTE, Minn., May 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2019 financial results on Thursday, May 9, 2019, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Apr 16, 2019 07:25 am ET
Investor Expectations to Drive Momentum within uniQure N.V., Aflac, ANI Pharmaceuticals, MaxLinear, ZAGG, and Aqua America — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of uniQure N.V. (NASDAQ:QURE), Aflac Incorporated (NYSE:AFL), ANI...
Apr 15, 2019 08:30 am ET
ANI Pharmaceuticals Expands Injectable Portfolio with Distribution Agreement for FDA Approved Injectable Product
BAUDETTE, Minn., April 15, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has entered into a Distribution Agreement with a U.S. based injectable manufacturer to commercialize a unique specialty injectable product.  Key terms of the 10-year Agreement include cumulative milestones of up to $2M, payable by ANI. Upon launch, ANI will receive a 50% share of net profits generated from product revenues. The product, for which there are currently no other generics commercially available, recently received FDA approval. The product will ...
Mar 27, 2019 08:30 am ET
ANI Pharmaceuticals Announces Two Generic Product Launches
BAUDETTE, Minn., March 27, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced the launch of 18mg and 27mg Methylphenidate Hydrochloride Extended-Release Tablets, indicated as a treatment for Attention Deficit Hyperactivity Disorder ("ADHD"). The current annual U.S. market for these two strengths of the product is approximately $505 million, according to Iqvia. ...
Feb 27, 2019 07:30 am ET
Feb 20, 2019 07:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Year-to-Date 2018 Financial Results
BAUDETTE, Minn., Feb. 20, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and year-to-date 2018 financial results on Wednesday, February 27, 2019, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Feb 13, 2019 07:40 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Amkor Technology, U.S. Silica, Steven Madden, Rowan Companies, SunOpta, and ANI Pharmaceuticals — New Research Emphasizes Economic G
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amkor Technology, Inc. (NASDAQ:AMKR), U.S. Silica Holdings, Inc....
Dec 27, 2018 03:30 pm ET
ANI Pharmaceuticals Secures Refinancing for Convertible Debt Due December 2019 and Enters Amended Five-Year $265 Million Senior Secured Credit Facility
BAUDETTE, Minn., Dec. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced that it has entered an amended and restated five-year Senior Secured Credit Facility (the "Facility") for up to $265.2 million with its existing syndicate of bank lenders (the "Bank Group"). The Facility amends ANI's current $125 million Senior Secured Credit Facility and is structured to provide ANI flexibility in refinancing its 3.00% Convertible Senior Notes due 2019 ("the Convertible Notes"). The principal feature of the Facility is a new $118.0 million Delayed...
Dec 07, 2018 07:00 am ET
ANI Pharmaceuticals Enters into Separate Privately Negotiated Agreements with Certain Holders of its Convertible Notes
BAUDETTE, Minn., Dec. 7, 2018 /PRNewswire/ -- (NASDAQ: ANIP) ANI Pharmaceuticals, Inc. (the "Company" or "ANI") today announced that it has entered into separate, privately negotiated agreements with certain holders of its outstanding 3.00% Convertible Senior Notes due 2019 (the "Notes"). ANI has agreed to repurchase $25.0 million aggregate principal amount of Notes for a total of $26.1 million in cash, including accrued but unpaid interest up to but excluding the closing date for the transactions. ...
Nov 15, 2018 08:15 am ET
ANI Pharmaceuticals, Inc. Ranked Number 366 Fastest Growing Company in North America on Deloitte's 2018 Technology Fast 500™
BAUDETTE, Minn., Nov. 15, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced it ranked No. 366 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. ANI revenue grew 216% during this period....
Nov 12, 2018 07:25 am ET
Research Report Identifies Canopy Growth, MSG Networks, ANI Pharmaceuticals, Mistras Group, Rowan Companies, and Chemours with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC), MSG Networks Inc. (NYSE:MSGN), ANI...
Nov 06, 2018 07:30 am ET
Oct 30, 2018 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2018 Financial Results
BAUDETTE, Minn., Oct. 30, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2018 financial results on Tuesday, November 6, 2018, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com. ...
Oct 18, 2018 09:00 am ET
Analysis: Positioning to Benefit within Clovis Oncology, Destination Maternity, MSG Networks, Lindblad Expeditions, NetScout, and ANI Pharmaceuticals — Research Highlights Growth, Revenue, and Consoli
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Clovis Oncology, Inc. (NASDAQ:CLVS), Destination Maternity Corporation...
Oct 16, 2018 09:00 am ET
ANI Announces Launch of Authorized Generic of Brethine®
BAUDETTE, Minn., Oct. 16, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq:ANIP) today announced the launch of Terbutaline Sulfate Tablets USP, 2.5mg and 5mg, an authorized generic of Brethine®. The current annual U.S. market for this product is approximately $11 million, according to Iqvia. Prior to ANI's launch there was only one supplier of the product in the U.S. market....
Oct 04, 2018 08:30 am ET
ANI Pharmaceuticals Announces Launch of Authorized Generic of Atacand HCT® Tablets
BAUDETTE, Minn., Oct. 4, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Candesartan Hydrochlorothiazide Tablets, 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg, an authorized generic of Atacand HCT®.  The current annual U.S. market for this product is approximately $20 million, according to Iqvia/IMS Health. ...
Sep 27, 2018 08:30 am ET
ANI Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
BAUDETTE, Minn., Sept. 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Wednesday, October 3, 2018 at 2:50 PM ET at the Cantor Fitzgerald Global Healthcare Conference in New York City. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/cantor7/anip/ and will be archived and available through the link through January 1, 2019. ...
Aug 27, 2018 07:45 am ET
Recent Analysis Shows KalVista Pharmaceuticals, IZEA, Sonic Automotive, Catabasis Pharmaceuticals, ANI Pharmaceuticals, and Clovis Oncology Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), IZEA Inc. (NASDAQ:IZEA),...
Aug 08, 2018 01:00 pm ET
ANI Pharmaceuticals to Present at New Time at the Canaccord Genuity 38th Annual Growth Conference
BAUDETTE, Minn., Aug. 8, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that, due to a scheduling change at Canaccord Genuity, ANI will now present on Thursday, August 9, 2018 at 2:00 PM ET at the Canaccord Genuity 38th Annual Growth Conference. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/canaccord30/anip/ and will be archived and available through the link through November 7, 2018. ...
Aug 07, 2018 08:30 am ET
Aug 06, 2018 08:30 am ET
ANI Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference
BAUDETTE, Minn., Aug. 6, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Thursday, August 9, 2018 at 2:30 PM ET at the Canaccord Genuity 38th Annual Growth Conference. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/canaccord30/anip/ and will be archived and available through the link through November 7, 2018. ...
Aug 01, 2018 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2018 Financial Results
BAUDETTE, Minn., Aug. 1, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2018 financial results on Tuesday, August 7, 2018, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Jun 27, 2018 08:00 am ET
ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP
BAUDETTE, Minn., June 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Cholestyramine for Oral Suspension USP, 4g/dose, in cans.  The current annual U.S. market for this product is approximately $22 million, according to Iqvia/IMS Health.  ...
Jun 25, 2018 07:50 am ET
Market Trends Toward New Normal in EnviroStar, Rowan Companies, Del Taco Restaurants, ANI Pharmaceuticals, Infinity Property and Casualty, and Viacom — Emerging Consolidated Expectations, Analyst Rati
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of EnviroStar, Inc. (NYSE:EVI), Rowan Companies PLC (NYSE:RDC), Del Taco...
Jun 05, 2018 08:30 am ET
ANI Shareholders Elect Three New Members to the Board of Directors
BAUDETTE, Minn., June 5, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced that the following three new members of the Board of Directors were elected at the Annual Meeting of Stockholders, held on May 17, 2018:...
May 08, 2018 08:30 am ET
May 07, 2018 08:30 am ET
ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
BAUDETTE, Minn., May 7, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has completed the acquisition of a portfolio of six generic products, related manufacturing and supply agreements, and equipment and technical know-how from Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) for cash consideration of $2.3 million.  The portfolio of generic products has a combined current annual U.S. market of $1.7 billion according to Iqvia/IMS Health.  ...
May 07, 2018 07:55 am ET
Market Trends Toward New Normal in Viacom, Nutanix, ANI Pharmaceuticals, PACCAR, Cabot Oil & Gas, and Box — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Viacom Inc. (NASDAQ:VIAB), Nutanix Inc. (NASDAQ:NTNX), ANI...
May 01, 2018 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results
BAUDETTE, Minn., May 1, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2018 financial results on Tuesday, May 8, 2018, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Apr 27, 2018 06:50 pm ET
Amneal And Impax Receive FTC Clearance For Business Combination
BRIDGEWATER, N.J., April 27, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Federal Trade Commission (FTC) has cleared the Amneal and Impax business combination, subject to Amneal and Impax's agreement to divest certain products. ...
Apr 27, 2018 06:30 pm ET
ANI Pharmaceuticals Signs Definitive Agreements to Acquire Generic Products and Assets from Amneal/Impax
BAUDETTE, Minn., April 27, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has signed definitive agreements to acquire a portfolio of generic products and other assets from Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc. (NASDAQ:IPXL) for undisclosed cash consideration.  The transaction is the result of a divestiture process mandated by the Federal Trade Commission ("FTC") in connection with Amneal Pharmaceutical's proposed business combination with Impax Laboratories.  The parties expect to close the transaction in early May. ...
Apr 18, 2018 08:30 am ET
ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution
BAUDETTE, Minn., April 18, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application ("ANDA") for Morphine Sulfate Oral Solution 10mg/5mL, 20mg/5mL and 100mg/5mL. The current annual U.S. market for this product is approximately $17 million, according to Iqvia/IMS Health. ANI expects to begin shipping product to its customers in the near future....
Apr 04, 2018 08:30 am ET
ANI Acquires 23 ANDAs from IDT Australia, Ltd.
BAUDETTE, Minn., April 4, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has acquired ANDAs for 23 previously marketed generic drug products from IDT Australia, Ltd. ("IDT") for $2.6 million and a limited single-digit royalty for one product. Additionally, ANI acquired active pharmaceutical ingredient for one of the acquired products for $135 thousand. In 2015, ANI had secured the U.S. licensing rights and 40% to 50% of the net profits upon commercialization for these products from IDT for $1.0 million. Today's acquisition gives ANI full control...
Mar 05, 2018 07:35 am ET
Detailed Research: Economic Perspectives on Lear, MYOS RENS Technology, Dollar Tree, Halliburton, Waters, and ANI Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lear Corporation (NYSE:LEA), MYOS RENS Technology...
Mar 02, 2018 07:30 am ET
ANI Pharmaceuticals to Present at the Raymond James 39th Annual Institutional Investors Conference
BAUDETTE, Minn., March 2, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Wednesday, March 7, 2018 at 11:35 AM ET at the Raymond James 39th Annual Institutional Investors Conference. Arthur S. Przybyl, President and CEO, will present on behalf of ANI Pharmaceuticals, Inc. Stephen P. Carey, Vice President, Finance and CFO, will also be in attendance and representing ANI. ...
Feb 27, 2018 09:00 am ET
ANI Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 10:30 AM Eastern Time.
Feb 27, 2018 07:30 am ET
Feb 20, 2018 07:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results and 2018 Guidance
BAUDETTE, Minn., Feb. 20, 2018 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and full year 2017 financial results and 2018 guidance on Tuesday, February 27, 2018, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com. ...
Dec 29, 2017 08:26 am ET
ANI Pharmaceuticals Enters Five-Year $125 Million Senior Secured Credit Facility with Citizens Bank
BAUDETTE, Minn., Dec. 29, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has entered a new five-year Senior Secured Credit Facility (the "Facility") for up to $125 million with Citizens Bank. The Facility is comprised of a $75 million five-year term loan that was closed today in support of ANI's acquisition of four NDAs acquired from AstraZeneca for $46.5 million in cash as previously announced this morning.  In addition, the term loan has been utilized to refinance existing indebtedness of $25 million that was outstanding against ANI's now reti...
Dec 29, 2017 08:21 am ET
ANI Pharmaceuticals Acquires Four NDAs from AstraZeneca for $46.5 Million
BAUDETTE, Minn., Dec. 29, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has acquired the NDAs and U.S. rights to market ATACAND®, ATACAND HCT®, ARIMIDEX®, and CASODEX® from AstraZeneca for $46.5 million in cash, royalties, and sales-based milestones.  AstraZeneca will continue to market and supply ATACAND®, ATACAND HCT®, ARIMIDEX®, and CASODEX® outside of the U.S. The acquired assets include the NDAs for all four products and a license to their trademarks.  The acquisitions were funded through a combination of cash and debt. ...
Nov 02, 2017 09:30 am ET
Nov 02, 2017 08:30 am ET
Report: Developing Opportunities within Echelon, NII Holdings, ANI Pharmaceuticals, Zion Oil & Gas, vTv Therapeutics, and Sears Holdings – Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Echelon Corporation (NASDAQ:ELON), NII Holdings, Inc....
Oct 26, 2017 09:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2017 Financial Results
BAUDETTE, Minn., Oct. 26, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2017 financial results on Thursday, November 2, 2017, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Sep 01, 2017 09:30 am ET
ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL
BAUDETTE, Minn., Sept. 1, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application ("ANDA") for Oxycodone Hydrochloride Oral Solution USP, 100 mg/5 mL (20 mg/mL). The current annual U.S. market for this product is approximately $14.5 million, according to IMS Health. ANI expects to begin shipping to its customers immediately....
Aug 08, 2017 09:30 am ET
ANI Pharmaceuticals to Present at the Canaccord Genuity 37th Annual Growth Conference
BAUDETTE, Minn, Aug. 8, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on Wednesday, August 9, 2017 at 4:30 PM ET at the Canaccord Genuity 37th Annual Growth Conference. Arthur S. Przybyl, President and CEO and Stephen P. Carey, Vice President, Finance and CFO, will present on behalf of ANI Pharmaceuticals, Inc. The presentation will be webcast live at http://wsw.com/webcast/canaccord26/anip, and will be archived and available through the link through November 7, 2017. ...
Aug 03, 2017 09:30 am ET
Jul 27, 2017 09:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2017 Financial Results
BAUDETTE, Minn., July 27, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2017 financial results on Thursday, August 3, 2017, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Jul 26, 2017 10:31 am ET
Options trade ideas for ANI Pharmaceuticals, Facebook, Gilead Sciences, Hilton Worldwide and Shutterfly offer returns of 21% or more!
CHICAGO, July 26, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ANIP, FB, GILD, HLT, and SFLY....
Jun 20, 2017 09:30 am ET
ANI Pharmaceuticals Announces Launch of Diphenoxylate HCl and Atropine Sulfate Tablets
BAUDETTE, Minn., June 20, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Diphenoxylate HCl and Atropine Sulfate Tablets, 2.5mg/0.025mg.  The annual U.S. market for Diphenoxylate HCl and Atropine Sulfate Tablets is approximately $56 million, per IMS Health.  Prior to ANI's launch there were two companies marketing a generic version of this drug product....
May 08, 2017 10:15 am ET
ANI Pharmaceuticals Announces Launch of Pindolol Tablets
BAUDETTE, Minn., May 8, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Pindolol Tablets, 5mg and 10mg, which is used in the treatment of hypertension. The annual U.S. market for Pindolol Tablets is approximately $10 million, per IMS Health....
May 04, 2017 09:30 am ET
Apr 27, 2017 09:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2017 Financial Results
BAUDETTE, Minn., April 27, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2017 financial results on Thursday, May 4, 2017, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Apr 19, 2017 09:30 am ET
ANI Pharmaceuticals Announces Launch of Indapamide Tablets
BAUDETTE, Minn., April 19, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced launch of Indapamide Tablets, 1.25mg and 2.5mg, which is used in the treatment of hypertension and swelling associated with congestive heart failure. The annual U.S. market for Indapamide Tablets is approximately $9 million, per IMS Health....
Mar 02, 2017 08:30 am ET
Feb 24, 2017 08:30 am ET
ANI Pharmaceuticals Acquires Inderal® XL and InnoPran XL®
BAUDETTE, Minn., Feb. 24, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has acquired Inderal® XL from Cranford Pharmaceuticals, LLC and InnoPran XL®  from Holmdel Pharmaceuticals LP.  The acquired assets include the NDA and trademark for InnoPran XL® including a license to an Orange Book listed patent, and a distribution license and trademark for Inderal® XL as well as finished goods inventory of both products.  Inderal® XL and InnoPran XL® are currently available in 80mg and 120mg sustained release capsules and are indicated for hypertension. ...
Feb 16, 2017 08:30 am ET
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2016 Financial Results and 2017 Guidance
BAUDETTE, Minn., Feb. 16, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and full year 2016 financial results and 2017 guidance on Thursday, March 2, 2017, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Jan 17, 2017 08:30 am ET
ANI Announces Appointment of Karen Quinn Ph.D as Vice President Corticotropin Regulatory Affairs
BAUDETTE, Minn., Jan. 17, 2017 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the appointment of Karen Quinn Ph.D as Vice President Corticotropin Regulatory Affairs, effective January 17, 2017.  ...
Dec 21, 2016 08:30 am ET
ANI Pharmaceuticals Announces Launch of Authorized Generic of Lithobid® Extended Release Tablets
BAUDETTE, Minn., Dec. 21, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Lithium Carbonate Extended Release Tablets, 300mg, an authorized generic of Lithobid®, which is used in the treatment of manic episodes of Bipolar Disorder. The annual US market for lithium carbonate is approximately $19 million, per IMS Health....
Dec 20, 2016 08:30 am ET
ANI Pharmaceuticals Announces Launch of Vancomycin Capsules in 50 Count Bottle
BAUDETTE, Minnesota, Dec. 20, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Vancomycin HCl 125mg and 250mg capsules, indicated for treatment of C. difficile-associated diarrhea, in a fifty count bottle.  The fifty count bottle of Vancomycin HCl capsules accounts for approximately 40% of the Vancomycin capsule volume and the annual US market for this bottle configuration is approximately $21 million, per IMS Health....
Nov 03, 2016 09:30 am ET
ANI Pharmaceuticals Reports Record Third Quarter Results and Year-To-Date 2016 Highlights and Narrows Full-year Guidance
BAUDETTE, Minn., Nov. 3, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported record financial results for the three and nine months ended September 30, 2016, and reaffirmed and narrowed its 2016 financial guidance. The Company will host its earnings conference call this morning, November 3, 2016, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (866) 776-8875. The conference ID is 93840986....
Oct 27, 2016 09:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2016 Financial Results
BAUDETTE, Minn., Oct. 27, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2016 financial results on Thursday, November 3, 2016, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com. ...
Oct 25, 2016 09:30 am ET
ANI Pharmaceuticals Announces Launch of Benztropine Mesylate Tablets USP
BAUDETTE, Minn., Oct. 25, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Benztropine Mesylate Tablets USP 0.5 mg, 1 mg and 2 mg. The current annual U.S. market for this product is approximately $25 million, according to IMS Health. ANI will immediately launch the product....
Sep 27, 2016 09:30 am ET
ANI Pharmaceuticals Announces Launch of Erythromycin Ethylsuccinate for Oral Suspension, 200mg/5mL
BAUDETTE, Minn., Sept. 27, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Erythromycin Ethylsuccinate for Oral Suspension 200mg/5mL indicated as a treatment for various infections.  The current annual U.S. market for this product is approximately $78 million, according to IMS Health, and is representative of two brand products.  ANI will immediately launch the product....
Aug 04, 2016 09:30 am ET
ANI Pharmaceuticals Reports Record Second Quarter Results and Increases Full-year 2016 Guidance
BAUDETTE, Minn., Aug. 4, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three and six months ended June 30, 2016, and increased its financial guidance for 2016. The Company will host its earnings conference call this morning, August 4, 2016, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (866) 776-8875. The conference ID is 47510730....
Jul 28, 2016 09:30 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss Second Quarter and Year-to-Date 2016 Financial Results
BAUDETTE, Minn., July 28, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its second quarter and year-to-date 2016 financial results on Thursday, August 4, 2016, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Jul 18, 2016 09:30 am ET
ANI Pharmaceuticals Announces FDA Approval and Immediate Launch of Nilutamide Tablets, the First Generic Competitor to Nilandron®
BAUDETTE, Minn., July 18, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of the Abbreviated New Drug Application ("ANDA") for nilutamide tablets.  Trailing twelve-month sales of Nilandron® were $23 million according to IMS Health.  ANI will immediately launch the product....
Jun 28, 2016 09:30 am ET
ANI Pharmaceuticals Announces Launch of Hydroxyprogesterone Caproate Injection USP, 250mg/mL
BAUDETTE, Minn., June 28, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of Hydroxyprogesterone Caproate Injection ("HPC") USP 250mg/mL in 5mL vials....
Jun 13, 2016 09:05 am ET
ANI Pharmaceuticals Announces FDA Approval of Oxcarbazepine Tablets
BAUDETTE, Minn., June 13, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of the Prior Approval Supplement ("PAS") for Oxcarbazepine Tablets, 150mg, 300mg and 600mg.  The current annual U.S. market for this product, based on trailing twelve months sales, is $145 million according to IMS Health....
Jun 13, 2016 09:00 am ET
ANI Pharmaceuticals Announces Launch of Oxycodone Capsules, 5mg
BAUDETTE, Minn., June 13, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of Oxycodone HCl Capsules, 5mg.  Trailing twelve-month sales for the product are $7.5 million according to IMS Health....
May 23, 2016 09:30 am ET
ANI Announces Appointment of Mark J. Ginski Ph.D as Vice President Corticotropin Product Development
BAUDETTE, Minn., May 23, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the appointment of Mark Ginski Ph.D as Vice President Corticotropin Product Development, effective May 23, 2016.  ...
May 18, 2016 09:00 am ET
ANI Pharmaceuticals to Present at the UBS Global Healthcare Conference
BAUDETTE, Minn., May 18, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present on May 23, 2016 at the UBS Global Healthcare Conference at the Grand Hyatt in New York City. On Monday, May 23, 2016 at 2:00 PM ET, Arthur S. Przybyl, President and CEO, will give the Company's presentation, which is posted on the Investor section of ANI's website at www.anipharmaceuticals.com. The presentation will be webcast live at https://cc.talkpoint.com/ubsx001/052316a_ae/?entity=62_R53VV6X, and will be archived and available through the link through August 21, 20...
May 17, 2016 10:00 am ET
ANI Pharmaceuticals Enters Into Exclusive Distribution and Supply Agreement for Hydroxyprogesterone Caproate Injection USP
BAUDETTE, Minn., May 17, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the signing of an exclusive distribution and supply agreement with Aspen Global Incorporated for Hydroxyprogesterone Caproate Injection ("HPC") USP 250mg/mL in 5mL vials.  Aspen will be responsible for supplying the finished goods and ANI Pharmaceuticals will be responsible for marketing and distribution in the U.S.  Aspen's product was approved by FDA in August 2015 (ANDA# 200271) and ANI intends to commercialize HPC in the near term. For product inquiries, please contact ANI at 21...
May 16, 2016 10:15 am ET
ANI Pharmaceuticals Launches Authorized Generic of Rowasa® Enema 4g/60mL
BAUDETTE, Minn., May 16, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of authorized generic Rowasa® (mesalamine) rectal suspension enema 4g/60ml in a 7x60ml carton.  According to IMS Health, sales for generic mesalamine rectal suspension enema 4g/60ml were $20.5 million, on a trailing twelve month basis....
May 13, 2016 10:00 am ET
ANI Pharmaceuticals Enters Three Year $30 Million Asset Based Line of Credit with Citizens Bank
BAUDETTE, Minnesota, May 13, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has entered a new three year senior secured asset-based revolving credit facility for up to $30 million. This facility will be secured by inventory and certain other working capital and related assets of ANI Pharmaceuticals, Inc....
May 09, 2016 09:00 am ET
ANI Pharmaceuticals Announces Launch of 50mg and 150mg Fenofibrate Capsules in ANI label
BAUDETTE, Minn., May 9, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of 50mg and 150mg fenofibrate capsules USP (the authorized generic of Lipofen®) in the ANI label.  The distribution rights to fenofibrate were acquired earlier this year and, as previously announced, ANI had expected to transition these products to the ANI label in the second quarter of 2016. In 2015 the authorized generic for Lipofen® (fenofibrate capsules 50mg and 150mg USP) generated $21.9 million in revenues. ...
May 05, 2016 09:00 am ET
ANI Pharmaceuticals Reports First Quarter Results and Year-To-Date 2016 Highlights and Reaffirms Updated Guidance
BAUDETTE, Minn., May 5, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three months ended March 31, 2016, and reaffirmed its financial guidance for 2016 as updated on April 4, 2016. The Company will host its earnings conference call this morning, May 5, 2016, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (844) 295-8236. The conference ID is 93601942....
Apr 27, 2016 09:05 am ET
ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2016 Financial Results and Reaffirm Guidance
BAUDETTE, Minn., April 27, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2016 financial results and reaffirm guidance on Thursday, May 5, 2016, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Apr 27, 2016 09:00 am ET
ANI Announces Appointment of Stephen P. Carey as Vice President and Chief Financial Officer
BAUDETTE, Minn., April 27, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the appointment of Stephen P. Carey to the position of Vice President and Chief Financial Officer, effective May 6, 2016....
Apr 05, 2016 09:05 am ET
ANI Pharmaceuticals Announces FDA Approval of Oxycodone Capsules, 5mg
BAUDETTE, Minn., April 5, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has received approval from the U.S. Food and Drug Administration ("FDA") of the Abbreviated New Drug Application ("ANDA") for Oxycodone HCl Capsules, 5mg.  Trailing twelve-month sales for the product are $7.5 million according to IMS Health....
Apr 05, 2016 09:00 am ET
ANI Pharmaceuticals Announces Launch of Hydrocortisone Rectal Cream 1% and 2.5%
BAUDETTE, Minn., April 5, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the commercial launch of 1% and 2.5% hydrocortisone cream for rectal use.  The combined market for these products was $84 million over the trailing twelve months through February 2016, according to IMS Health.  ...
Apr 04, 2016 09:05 am ET
ANI Pharmaceuticals Updates 2016 Financial Guidance
BAUDETTE, Minn., April 4, 2016 /PRNewswire/ -- As a result of the close of the acquisition of the Inderal® LA assets from Cranford Pharmaceuticals, ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today issued revised financial guidance for 2016....
Apr 04, 2016 09:00 am ET
ANI Pharmaceuticals Closes Acquisition of Inderal® LA Assets
BAUDETTE, Minn., April 4, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has completed the acquisition of the portfolio of Inderal® LA assets from Cranford Pharmaceuticals, LLC.  As previously communicated, the acquired portfolio includes the NDA and trademark for Inderal® LA as well as finished goods inventory.  The acquisition was funded through cash on hand....
Mar 11, 2016 08:00 am ET
ANI Pharmaceuticals Agrees to Acquire Inderal® LA Assets from Cranford Pharmaceuticals
BAUDETTE, Minn., March 11, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has agreed to acquire a portfolio of Inderal® LA assets from Cranford Pharmaceuticals, LLC. The acquired portfolio will include the NDA and trademark for Inderal® LA as well as finished goods inventory. Cranford Pharmaceuticals, LLC owns the NDA for Inderal® LA 60mg, 80mg, 120mg and 160mg sustained release capsules as well as the authorized generic, propranolol ER capsules, both of which are indicated for hypertension, angina pectoris, migraine and hypertrophic subaortic s...
Mar 09, 2016 08:00 am ET
ANI Pharmaceuticals to Present at 28th Annual ROTH Conference
BAUDETTE, Minn., March 9, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that it will present at the 28th Annual ROTH Conference at the Ritz-Carlton at Laguna Niguel, California. On March 14, 2016 at 11:30 AM PT, Arthur S. Przybyl, President and CEO, will give the Company's presentation, which is posted on the Investor section of ANI's website at www.anipharmaceuticals.com. Mr. Przybyl's presentation will be webcast live at http://wsw.com/webcast/roth30/anip, and archived and available through the link through June 12, 2016....
Feb 24, 2016 08:00 am ET
ANI Pharmaceuticals and Dexcel Announce FDA Approval of Donepezil Hydrochloride 23mg Tablets
BAUDETTE, Minn., Feb. 24, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today announced that its collaboration partner Dexcel Pharma Technologies Ltd. ("Dexcel")  has received approval from the U.S. Food and Drug Administration ("FDA") of the Abbreviated New Drug Application ("ANDA") for Donepezil HCl 23mg Tablets. Sales of the product for calendar year 2015 were $44 million, according to IMS Health, with five current generic competitors.  ANI and Dexcel expect to begin shipping to customers shortly. ...
Feb 23, 2016 08:00 am ET
ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results and Provides 2016 Guidance
BAUDETTE, Minn., Feb. 23, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) today reported financial results for the three and twelve months ended December 31, 2015, and provided its financial guidance for the 2016 year. The Company will host its earnings conference call this morning, February 23, 2016, at 10:30 AM ET. Investors and other interested parties can join the call by dialing (844) 295-8236. The conference ID is 48813555....
Feb 16, 2016 08:00 am ET
ANI Pharmaceuticals Schedules Conference Call for Fourth Quarter and Full Year 2015 Financial Results and 2016 Guidance
BAUDETTE, Minn., Feb. 16, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and full year 2015 financial results and 2016 guidance on Tuesday, February 23, 2016, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com....
Feb 01, 2016 08:00 am ET
ANI Pharmaceuticals Acquires Exclusive Rights to Distribute Three Generic Drug Products from H2-Pharma for $10 Million
BAUDETTE, Minn., Feb. 1, 2016 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that it has acquired the exclusive rights to distribute 1% and 2.5% hydrocortisone cream for rectal use and the exclusive rights to distribute the authorized generic of Lipofen® (fenofibrate capsules 50mg and 150mg USP) from H2-Pharma, LLC.  In addition, ANI also acquired an early stage development project for an undisclosed generic injectable drug product.  ...